Research Briefs

Key Drivers of HTA Decisions for "Life-Changing" Drugs

There are mechanisms in place to reward innovative and “life-changing” drugs. Most of these mechanisms exist in the regulatory process, but what about the reimbursement process? Are “life-changing” drugs rewarded by health technology assessment (HTA) agencies with positive reimbursement decisions? This original research applies a data-driven approach to evaluate the key drivers of HTA agency decisions for drugs that provided significant improvement in benefits over existing therapies.